Abstract
Clinically approved for the treatment of diabetes and obesity, glucagon-like peptide-1 (GLP-1) receptor agonists display prominent glucose- and weight-lowering effects as well as positive cardioprotective and neuroprotective actions. Despite these benefits, bariatric surgery remains superior in producing robust and sustained weight loss alongside improvements in metabolic control with possible diabetes remission. The current review considers the potential for adjunct therapies to augment the therapeutic actions of GLP-1 receptor agonists. In this regard, several gut-derived hormones also, modulated by bariatric surgery, display additive properties when combined with GLP-1 receptor agonists in both preclinical and clinical studies. In addition, glucocorticoids and oestrogen have shown promise in augmenting the biological actions of GLP-1 in animal models. Additionally, GLP-1 efficacy can also be enhanced by use of compounds that prolong GLP-1 receptor coupling to potentiate downstream receptor signalling. Taken together, therapies that activate GLP-1 receptor signalling, in combination with various other cell signalling pathways, show potential for treating type 2 diabetes and obesity with superiority over GLP-1 receptor agonist therapy alone.
| Original language | English |
|---|---|
| Article number | e14699 |
| Pages (from-to) | e14699 |
| Journal | Diabetes Medicine |
| Volume | 38 |
| Issue number | 12 |
| DOIs | |
| Publication status | Published (in print/issue) - Dec 2021 |
Bibliographical note
Funding Information:Work on peptide therapeutics and GLP‐1 analogues within the authors’ laboratory has been generously supported by Diabetes UK, Invest Northern Ireland, NI Department for Education, Ulster University and a project grant from European Foundation for the Study of Diabetes that employs NT.
Publisher Copyright:
© 2021 Diabetes UK
Keywords
- CCK
- GIP
- GLP-1
- Glucagon
- PYY
- diabetes
- gastrin
- obesity
- xenin
- glucagon
